Pathway Genomics Partners with DASA
News Jun 25, 2012
DASA's brands include Alta Excelencia Diagnostica, Delboni Auriemo, Lavoisier, CDPI, Sergio Franco, Pasteur, Exame and others. Through this partnership, physicians have access to Pathway's valuable genetic testing services, bringing additional personalized care to more than 180 million people in Brazil.
"Pathway's vision is to responsibly reveal personalized and actionable genetic information in order to globally educate, inform and improve health and well-being," said Dr. Michael Nova, Pathway's chief medical officer. "Our alignment with DASA is a major part of this vision, and we are excited to help bring this scientifically-advanced technology to the people of Brazil."
Specifically, through DASA, physicians in Brazil now have access to multiple genetic tests, including:
-- Pathway Fit(R), which addresses a patient's food metabolism and exercise response. The test has recently shown positive results with a clinical trial by California Schools VEBA, of which, 179 employees showed significant weight loss success compared to controls.
-- Cardiac Health Insighta", Pathway's new cardiac panel developed with input from some of the world's leading cardiology centers. The genetic test offers physicians insight into how a patient's genes may affect heart-related conditions, including various drug responses and genetic risk for developing certain cardiovascular diseases, including sequencing of certain monogenic conditions.
"The partnership between DASA and Pathway represents a milestone in Brazilian medicine, ensuring access to predictive genetic tests through an advanced and innovative technology," said Dr. Octavio Fernandes, DASA's chief operating officer. "DASA is a reference in Brazil due to our excellence, innovation and quality in medical diagnostic services. With 50 years of expertise, the company has one of the largest medical teams in Latin America, composed of nearly 2,000 world-renowned doctors, and offering more than 3,000 types of laboratory tests and imaging diagnostics provided by more than 18,000 professionals."
Pathway's laboratory is accredited by the College of American Pathologists (CAP) and accredited in accordance with the U.S. Health and Human Services' Clinical Laboratory Improvement Amendments (CLIA) of 1988. Pathway is also a member of the American Clinical Laboratory Association (ACLA). The company consists of more than 40 scientific and medical professionals, including medical doctors, molecular geneticists, and genetic counselors, as well as an expert scientific advisory board.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.